Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Wiggans, Alison J ^a   Cass, Gemma K S ^a   Bryant, Andrew ^b   Lawrie, Theresa A ^c   Morrison, Jo ^a  

^a MUSGROVE PARK HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; OLAPARIB; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FOLLOW UP; HUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; DNA REPAIR; DRUG EFFECTS; FEMALE; GENETICS; META ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DISEASE-FREE SURVIVAL; DNA REPAIR; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84945386270     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007929.pub3     Document Type: Review

References (80)

1. Kaye SB. ICEBERG3. http://clinicaltrials.gov/show/NCT00628251. ClinicalTrials.gov, 26 February 2008.
2. Kaye SB, Lubinski J, Matulonis U, Ang J E, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology 2012;30(4):372-9.
3. Kummar S, Fleming GF, Oza AM, Sullivan DM, Gandara DR, Naughton M, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clinical Cancer Research 2015;14:2562. [DOI: 10.1158/1078-0432.CCR-14-2565]
4. Kummar S, Oza A, Fleming G, Sullivan D, Gandara D, Erlichman C, et al. Randomized trial of oral cyclophosphamide with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting. Journal of Clinical Oncology 2012;30(15 Suppl):5020. [: http://meetinglibrary.asco.org/content/98169-114]
5. Ledermann J. Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer. http://clinicaltrials.gov/show/NCT00753545 12 September 2008.
6. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). International journal of gynecological cancer. 2011; Vol. 21 (S13).
7. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet oncology 2014;15(8):852-861.
8. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine 2012;366(15):1382-92.
9. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Obstetrical & gynecological survey 2015;69((10)):594-596.
10. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJS, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Journal of clinical oncology. 2011; Vol. 29.
11. Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJS, Fielding A, Spencer S, Ho TW, Ledermann JA. Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-55. 2014.
12. Oza A, Cibula D, Oaknin Benzaquen A, Poole C, Mathijssen RHJ, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncology 2015;; Vol. 16, issue 1:87-97.
13. Oza AM, Cibula D, Oaknin A, Poole CJ, Mathijssen RHJ, Sonke GS, et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. Journal of Clinical Oncology 2012;30(15 Suppl):5001. [: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/5001]
14. Oza AM, Cibula D, Oaknin Benzaquen A, Poole CJ, Mathijssen RHJ, et al. Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses. European Journal of Cancer 2013;49 Suppl 2:S712-S3.
15. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology 2008;26(22):3785-90.
16. Audeh MW, Penson RT, Friedlander M. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. Journal of Clinical Oncology (Meeting Abstracts) 2009;27(15S):5500.
17. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376(9737):245-51.
18. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clinical Cancer Research 2013;19(5):961-8.
19. Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Archives of Gynecology and Obstetrics 2013;288(2):367-74.
20. Coleman RL, Sill M, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen HX, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - A Gynecologic Oncology Group study. Gynecologic oncology. 2014; Vol. 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:56-57.
21. Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Annals of the New York Academy of Science 2008;1138:136-45.
22. Fong PC, Spicer J, Reade S. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. Journal of Clinical Oncology (Meeting Abstracts) 2006;24(18 Suppl):3022.
23. Fong PC, Boss DS, Carden CP. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of Clinical Oncology (Meeting Abstracts) 2008;26(15 Suppl):5510.
24. Fong PC, Boss DS, Yap TA. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New England Journal of Medicine 2009;361(2):123-34.
25. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncology 2011;12(9):852-61.
26. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 2008;8(3):193-204.
27. Lee J-M, Liu J, Choyke PL, Elbuluk O, Turkbey IB, Trepel JB, Lee M-J, Cao L, Houston ND, Gordon N, Figg WD, Barry WT, Matulonis U, Birrer MJ, Ivy P, Kohn EC. Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648). Journal of clinical oncology. 2014; Vol. 32:5s:(suppl; abstr 5535).
28. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Current Opinion in Pharmacology 2008;8(4):363-9.
29. Liu J, Barry WT, Birrer MJ, Lee J-M, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam SR, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts. 32(15_suppl); Vol. LBA550.
30. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet oncology 2014;15(11):1207-1214.
31. Moore KN, Zhang X-Y, Agarwal S, Patel MR, Burris HA, Martell RE, Kansra, V . Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts. May 2014; Vol. 32(15_suppl):e16531.
32. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecologic Oncology 2009;112(1):275-81.
33. McNeish I, Coleman RL, Oza A, Konecny G, O'Malley DM, Kichenadasse G, et al. Preliminary results of ARIEL2, a phase 2 open-label study to identify ovarian cancer patients likely to respond to rucaparib. Annals of Oncology 2014;25(Suppl 4):iv305-26. [: clovistrials@emergingmed.com;: https://clinicaltrials.gov/ct2/show/NCT01891344]
34. Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. OncoTargets and Therapy 2013;6:1197-206.
35. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Current Opinion in Pharmacology 2005;5(4):388-93.
36. Yap TA, Boss DS, Fong PC. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. Journal of Clinical Oncology (Meeting Abstracts) 2007;25(18 Suppl):3529.
37. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer 2009;9(3):167-81.
38. DiSilvestro P, Moore K. A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy. https://clinicaltrials.gov/ct2/show/NCT01844986 2013.
39. Moore KN, DiSilvestro P, Lowe ES, Garnett S Pujade-Lauraine E. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). J Clin Oncol (Meeting Abstracts). May 2014; Vol. 32 (15-suppl):TPS5616.
40. Matulonis U, Mahner S, Wenham RM, Ledermann JA, Monk BJ, Del Campo JM, Berek JS, Vergote I, Fabbro M, Katsaros D, Marth C, Lorusso D, Herrstedt J, Agarwal S, RMartell RE, Mirza MR. A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts. 32(15_sppl); Vol. TPS5625.
41. Mirza M, Berek JS, Vergote I, Wenham RM, Del Campo JM, Oza AM, Mahner S, Monk BJ, Fabbro M, Ledermann JA, Marth C, Bruchim I, Katsaros D, Lorusso D, Malander S, Dorum A, Agarwal S, Martell RE, Matulonis U. Engot-ov16/nova: A phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer. International journal of gynecological cancer 2014;Conference: 15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia. Conference Start: 20141108 Conference End: 20141111. Conference Publication. 2014:33-34.
42. Mirza MR, Matulonis U. A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer. https://clinicaltrials.gov/ct2/show/NCT01847274 2013.
43. Moore KN, DiSilvestro P, Lowe ES, Garnett S Pujade-Lauraine E. SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616. 2014.
44. Pujade-Lauraine E. Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy. https://clinicaltrials.gov/NCT01874353 2013.
45. A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3). ClinicalTrials.gov website 6 April 2015. [: https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&rank=1]
46. Swisher EM, McNeish IA, ColemanRL, Brenton J, Kaufmann SH, A Allen AR, Raponi M, Giordano H, Maloney L, JIsaacson J, aLedermann JA. ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. J Clin Oncol (Meeting Abstracts) vol. 32 no. 15_suppl TPS5619. May 2014; Vol. 32 (15_suppl):TPS5619.
47. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434(7035):913-7.
48. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Research 2006;34(6):1685-91.
49. Cancer Therapy Evaluation Program (CTEP), Common Terminology Criteria for Adverse Events, Version 4.03, DCTD, NCI, NIH, DHHS. US Department of Health and Human Services (http://ctep.cancer.gov) May 2009; updated June 2010, issue NIH Publication No. 09-5410.
50. Curtin NJ. PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine 2005;7(4):1-20.
51. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
52. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
53. Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency. Summary of opinion (initial authorisation): Lynparza (olaparib). European Medicines Agency, London 23 October 2014.
54. Adept Scientific Ltd. Endnote X6. Letchworth, UK: Adept Scientific Ltd., 2012.
55. Erickson BK, Conner MC, Landen CN. The role of the fallopian tube in the origin of ovarian cancer. American Journal of Obstetrics and Gynecology Nov 2013;209(5):409-14.
56. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917-21.
57. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase 2013, issue No. 11 [Internet].
58. McMaster University. GRADEpro[Computer program on www.gradepro.org]. Version [Jan 2015]. McMaster University, 2014.
59. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. Journal of Clinical Oncology 2010;28(22):3570-6.
60. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
61. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
62. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. National Reviews of Drug Discovery 2005;4(5):421-40.
63. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58(2):71-96.
64. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD005343]
65. National Institute for Clinical Excellence. Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer - guidance (CG164). London: National Institute for Clinical Excellence, 2013.
66. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
67. Peralta-Leal A, Rodriguez MI, Oliver FJ. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clinical Translations in Oncology 2008;10(6):318-23.
68. Quinn M, Babb B, Brock A, Jones J. Cancer Trends in England and Wales. London: The Stationery Office, 2001.
69. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clinical Cancer Research 2007;13(5):1383-8.
70. Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Frontiers in Oncology 2013;3(237):1-11.
71. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
72. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 2001;68(3):700-10.
73. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889-92.
74. Stewart L, Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001418]
75. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Reviews Cancer 2004;4:814-9.
76. Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, et al. EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). Proceedings of the 12th Biennial Meeting of the International Gynecologic Cancer Society - IGCS. Bangkok, 2008.
77. Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the anti-tumor effects of chemo-radiation treatment by down-regulating DNA repair proteins. Molecular Cancer Therapeutics 2011;10:1241-51.
78. Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anti-cancer Agents in Medicinal Chemistry 2007;7(5):515-23.
79. Martinek I, Haldar K, Gaitskell K, Nicum S, Kehoe S, Morrison J. DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007929]
80. Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J. DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD007929.pub2]